Bausch Health Companies Inc.
BHCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Bausch Health Companies Inc. (BHC) is listed under Drug Manufacturers - Specialty & Generic. At a $2.02B market cap, Bausch Health Companies Inc. ranks as a mid-cap company within healthcare. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Market Cap
$2.02B
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
1.33
EPS (TTM)
$-3.25
EPS (Fwd)
$4.06
ROE
—
ROA
5.9%
Cash
$1.30B
Total Debt
$20.80B
Free CF
$1.12B
52W Change
19.4%
Annual Financials
Cash vs Debt
On the balance sheet, BHC has $1.30B in cash with $20.80B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $1.12B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $8.12B (2022) to $10.27B (2025), reflecting a 26% increase over the period.
With a beta below 0.7, Bausch Health Companies Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BHC.